WO2005033301A1 - 細胞活性化方法及びこれを用いる細胞製造方法並びに医薬組成物 - Google Patents
細胞活性化方法及びこれを用いる細胞製造方法並びに医薬組成物 Download PDFInfo
- Publication number
- WO2005033301A1 WO2005033301A1 PCT/JP2004/014170 JP2004014170W WO2005033301A1 WO 2005033301 A1 WO2005033301 A1 WO 2005033301A1 JP 2004014170 W JP2004014170 W JP 2004014170W WO 2005033301 A1 WO2005033301 A1 WO 2005033301A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- antibody
- cytotoxic
- fragment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 41
- 230000020411 cell activation Effects 0.000 title claims description 22
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 239000000203 mixture Substances 0.000 title abstract description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 209
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 115
- 108010065524 CD52 Antigen Proteins 0.000 claims abstract description 73
- 102000013135 CD52 Antigen Human genes 0.000 claims abstract description 73
- 239000000556 agonist Substances 0.000 claims abstract description 44
- 230000000638 stimulation Effects 0.000 claims abstract description 27
- 229940122738 CD3 agonist Drugs 0.000 claims abstract description 15
- 239000002243 precursor Substances 0.000 claims abstract description 13
- 210000000130 stem cell Anatomy 0.000 claims description 97
- 230000001472 cytotoxic effect Effects 0.000 claims description 86
- 239000012634 fragment Substances 0.000 claims description 70
- 239000008194 pharmaceutical composition Substances 0.000 claims description 70
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 230000000694 effects Effects 0.000 claims description 46
- 231100000433 cytotoxic Toxicity 0.000 claims description 45
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 43
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 claims description 43
- 239000000427 antigen Substances 0.000 claims description 37
- 108091007433 antigens Proteins 0.000 claims description 37
- 102000036639 antigens Human genes 0.000 claims description 37
- 206010036790 Productive cough Diseases 0.000 claims description 20
- 208000024794 sputum Diseases 0.000 claims description 20
- 210000003802 sputum Anatomy 0.000 claims description 20
- 238000003556 assay Methods 0.000 claims description 17
- 210000001165 lymph node Anatomy 0.000 claims description 16
- 230000003013 cytotoxicity Effects 0.000 claims description 10
- 231100000135 cytotoxicity Toxicity 0.000 claims description 10
- 210000005259 peripheral blood Anatomy 0.000 claims description 7
- 239000011886 peripheral blood Substances 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 206010003445 Ascites Diseases 0.000 claims description 4
- 210000004700 fetal blood Anatomy 0.000 claims description 4
- 210000001541 thymus gland Anatomy 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000000557 podocyte Anatomy 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 abstract description 8
- 230000001404 mediated effect Effects 0.000 abstract 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 43
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 43
- 210000001744 T-lymphocyte Anatomy 0.000 description 38
- 210000004881 tumor cell Anatomy 0.000 description 35
- 238000012360 testing method Methods 0.000 description 30
- 201000011510 cancer Diseases 0.000 description 25
- 230000004940 costimulation Effects 0.000 description 25
- 238000002560 therapeutic procedure Methods 0.000 description 21
- 102000009410 Chemokine receptor Human genes 0.000 description 16
- 108050000299 Chemokine receptor Proteins 0.000 description 16
- 102000004503 Perforin Human genes 0.000 description 15
- 108010056995 Perforin Proteins 0.000 description 15
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 15
- 229930192851 perforin Natural products 0.000 description 15
- 238000011579 SCID mouse model Methods 0.000 description 13
- 102000000588 Interleukin-2 Human genes 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 11
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 108091008874 T cell receptors Proteins 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 230000001747 exhibiting effect Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000035605 chemotaxis Effects 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000003399 chemotactic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 208000002151 Pleural effusion Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 210000000581 natural killer T-cell Anatomy 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 2
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- -1 was available Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 101100400999 Caenorhabditis elegans mel-28 gene Proteins 0.000 description 1
- 108010083702 Chemokine CCL21 Proteins 0.000 description 1
- 102000006435 Chemokine CCL21 Human genes 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000750631 Takifugu chinensis Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/53—Liver
Definitions
- the present invention is directed to cytotoxic T cells for inducing differentiation, promoting proliferation and enhancing functions of cytotoxic T cells (CD8 killer T cells, CTL) that attack tumor cells, virus-infected cells, and the like.
- the present invention also relates to a cell activation method for activating immune cells comprising the precursor cells thereof, a cell production method using the same, and a pharmaceutical composition.
- Patent Document 1 Japanese Patent Application Laid-Open No. 2003-102471
- Examples of so-called cancer immunotherapy that treats cancer using the immune function of a living body include, for example, tumor-specific antigens, vaccines that use BCG that enhances immune ability, and monoclonals that specifically attack cancer cells.
- a method that uses biologics that have antibody strength and so-called adoptive immunotherapy in which immunocompetent cells removed from the living body are appropriately treated to have anticancer functions, and the immunocompetent cells with anticancer functions are returned to the living body. And so on.
- adoptive immunotherapy for example, monocytes (mononuclear cells) are taken out from the peripheral blood of a living body, and the taken out monocytes are separated to proliferate the rod cells, and the grown rod cells are treated with a tumor antigen.
- rod-shaped cells treated with the tumor antigen are returned to the living body!
- rod cells are thought to induce cytotoxic T cells that specifically attack tumor cells in vivo.
- cytotoxic T cells for example, natural killer cells (hereinafter referred to as NK cells) and natural killer T cells (hereinafter referred to as NKT cells) having non-specific anti-cancer action are taken out of the living body and activated to be activated.
- NK cells natural killer cells
- NKT cells natural killer T cells having non-specific anti-cancer action
- LAK lymphokine-activated killer
- IL 2 human interleukin 2
- LAK cells with antitumor activity which is one of the NK cells obtained by culturing in the presence of IL 2 at a concentration, are transferred into the body of cancer patients, and at the same time, a high dose of IL 2 is administered.
- LAK therapy has been reported to be effective in 11 of 25 cases of malignant melanoma or renal cancer, no effect has been observed in the follow-up tests after that report. The therapeutic effect of LAK therapy alone is difficult to recognize due to poor medical evidence.
- TIL lymphocytes
- TIL therapy is effective for malignant melanoma, locally recurrent breast cancer, cancerous pleural effusion, cancerous ascites, hepatocellular carcinoma, colon cancer, non-Hodgkin's lymphoma, etc.
- TIL requires a long-term culture for proliferation, TIL accumulation into the tumor may reduce the antitumor activity, and cells that suppress the antitumor effect have appeared. There is also a risk of it.
- T cells as precursor cells of cytotoxic T cells and antigen-presenting cells such as rod cells are co-cultured.
- TCR T cell receptor
- the T cell receptor (TCR) of a T cell having a CD8 molecule recognizes an antigen peptide bound to an HLA class 1 molecule of an antigen presenting cell.
- tumor antigen-treated rod-shaped cells and tumor antigen-specific cytotoxic ⁇ cells are induced to differentiate in large quantities in vitro.
- Research has been done on how to return to As such a method for example, tumor-specific cytotoxic T cells or cytotoxic T cell clones are induced by culturing rod-shaped cells incorporating tumor antigens with autologous peripheral blood lymphocytes.
- Dudley ME et al., J. Immunother. 25: 243-51, 2002
- self-activating lymphocyte transfer therapy for cancer has been performed as a highly advanced medical treatment at some universities and private medical facilities.
- Such self-activated lymphocyte transfer therapy includes, for example, stimulating peripheral blood lymphocytes with anti-CD3 antibody, culturing and proliferating for a long period of time with IL 2, and treating the proliferated peripheral blood lymphocytes to cancer patients.
- V so-called CD3—LAK therapy is a relatively simple therapy.
- Cells that are activated by CD3—LAK therapy and have antitumor activity are mainly CD8T cells. It is not activated NK cells used in therapy (Ochoa AC et al., J. Immun ol. 138: 2728, 1987).
- CD3-LAK therapy is currently used for various cancers, and it has been reported that recurrence-suppressing effect is particularly observed after hepatocellular carcinoma healing. 3 ⁇ 4 (Takayama T et al., Lancet 356: 802, 2000).
- the reason for the low response rate of CD3—LAK therapy to cancer is that perforin expression of the first proliferated cytotoxic T cells is low, and secondly, chemokines for migrating to lymph nodes It is thought that receptors, especially CCR7, may lose cytotoxic T cell power.
- cytotoxic T cell or its T Progenitor cells need to receive two signals from antigen-specific T cell receptor (TCR) and costimulatory molecules (usually CD28 molecules), and cytotoxic T cells or their progenitor cells are TCR Received only one signal through
- TCR antigen-specific T cell receptor
- costimulatory molecules usually CD28 molecules
- the second reason for the low response rate of CD3—LAK therapy to cancer is that cytotoxic ⁇ cells proliferated by CD3—LAK therapy migrated to peripheral lymph nodes. Because the required chemokine receptors, especially CCR7, are not very expressed, cytotoxic sputum cells administered to the body cannot reach the peripheral lymph nodes, and therefore, for cancer that has metastasized to the peripheral lymph nodes. It is considered that the effect cannot be exerted. In addition, it is considered extremely important to prevent cancer metastasis to peripheral lymph nodes that generate tumor immune responses.
- the present inventors have shown that regulatory T cells derived from CD4 positive T cells having an inhibitory action on other T cells are induced by the action of anti-4C8 antibody (Masuyam a , J. et al., J. Immunol. 169: 3710, 2002), and the induction of such regulatory T cells is also shown in Patent Document 1.
- anti-CD52 antibody anti-4C8 antibody
- anti-4C8 antibody has transvascular endothelial cell migration inhibitory activity! (Masuyama, J. et al., J. Exp. Med. 189: 979, 1999; W099Zl2972).
- cytotoxic T cells or their progenitor cells via CD52 molecules with anti-4C8 antibody etc. Research has been done to kill tumor cells, virus-infected cells, etc. based on cytotoxic ⁇ cells or progenitor cells to which costimulation has been given.
- the present invention has been made in view of the above-mentioned points, and its object is to provide cytotoxicity having non-specific cytotoxic activity against various tumor cells, virus-infected cells and the like. It is an object of the present invention to provide a cell activity method that can easily obtain T cells in a short period of time, a cell production method using the same, and a pharmaceutical composition.
- Another object of the present invention is to provide cytotoxic T cells having non-specific cytotoxic activity against various tumor cells, virus-infected cells and the like, and pharmaceutical compositions containing the same. There is.
- a cytotoxic T cell or a progenitor cell thereof is stimulated by a CD3 agonist and a CD52 agonist.
- cytotoxic T cells are transmitted via CD3 molecules and CD52 molecules by CD3 and CD52 agonists.
- cytotoxic T cells or progenitor cells can be generated with a strong activity, and thus activated cytotoxic T cells Cytotoxic T cells that are able to promote proliferation by causing strong differentiation induction in cells or their progenitor cells, and thus are highly expressed by chemokine receptors, especially CCR7, and can migrate to lymph nodes
- chemokine receptors especially CCR7
- the cytotoxic T cells obtained by using the cell activity assay method of the first aspect can more accurately separate normal cells from tumor cells than other immune cells.
- the cytotoxic T cells obtained based on the cell activation method of the first aspect by the cell activation method It is possible to obtain cytotoxic T cells exhibiting strong and non-specific cytotoxic activity against various tumor cells, virus-infected cells and the like.
- the cell activation method according to the first aspect capable of exhibiting such an effect is a disease such as a malignant tumor, a virus infection or the like * directly (for example, administration of an agonist to a living body) for treatment of a disease state or It can be used indirectly (such as the production of cytotoxic T cells).
- the present inventor has intensively studied on the cytotoxicity of CD52 antigens such as anti-4C8 antibody, etc. with respect to the effect on cells or its precursor cells, Obtained by stimulating (co-stimulating) cytotoxic CD cells or their progenitor cells via CD3 and CD52 molecules by CD3 and CD52 agonists.
- Cytotoxicity Vaginal cells or their progenitor cell strengths When chemokine receptors, particularly CCR7, are highly expressed, they can be constructed for the first time based on the results.
- the CD52 antigen has an anti-4C8 antibody or a fragment thereof.
- the CD52 antigen in the cell activation method of the first or second aspect, has campus-1H or a fragment thereof.
- cytotoxicity is induced by anti-4C8 antibody or a fragment thereof or campus 1H or a fragment thereof.
- many cytotoxic sputum cells can express chemokine receptors, in particular CCR7, and in particular, cytotoxic sputum cells or fragments by anti-4C8 antibodies or fragments thereof.
- costimulation to the progenitor cells, it is possible to express chemokine receptors, particularly CCR7, in more cytotoxic sputum cells.
- the first force is the cell activity method according to any one of the third aspects.
- the cell activity assay method of the fourth aspect is characterized in that V, and one site of the CD52 molecule of the cytotoxic epithelial cell or its progenitor cell.
- the antibody or fragment thereof that binds to the antibody consists of an anti-4C8 antibody or fragment thereof, and Other antibodies or fragments thereof that bind to other sites of the CD52 molecule of sex T cells or their progenitor cells consist of campus 1H or fragments thereof.
- an anti-4C8 antibody or a fragment thereof is bound to one site of the CD52 molecule.
- the cytotoxic or progenitor cell can be suitably activated.
- the first force in the cell activity assay method of any of the fifth aspect is a CD3 agonist is a cytotoxic cell or a cell thereof. It has an anti-CD3 antibody or a fragment thereof that binds to the CD3 molecule of progenitor cells.
- the first force is the cell activity determination method according to any one of the sixth aspect, wherein at least one of the CD3 agonist and the CD52 agonist is
- Having at least one of a humanized antibody and a human antibody Having at least one of a humanized antibody and a human antibody.
- the human antibody is mouse humanized antibody or rat human antibody antibody campus-1H.
- the CD3 agonist and the CD52 agonist in vitro or in vivo according to the cell activation method according to any one of the eighth aspect of the first force. Stimulates cytotoxic sputum cells or their progenitor cells.
- the cell activity assay method of the tenth aspect of the present invention is the cell activity assay method according to any one of the first aspect of the ninth aspect, wherein the peripheral activity is controlled by CD3 antigen and CD52 agonist. Stimulates cytotoxic sputum cells or progenitor cells that can be present in blood, lymph nodes, thymus, bone marrow, tumor, pleural effusion, ascites or umbilical cord blood.
- the cell production method of the present invention produces cytotoxic sputum cells using the cell activation methods of any one of the first to tenth aspects.
- the cytotoxic sputum cell of the present invention can be obtained by the cell activity assay method of any one of the first to tenth aspects.
- the present invention is different from the pharmaceutical composition of each aspect described later by a pharmaceutical composition containing cytotoxic ⁇ cells obtained by the method for cell activation according to any one of the first to tenth aspects. It can be configured as one aspect of.
- the pharmaceutical composition according to the first aspect of the present invention is a method for inserting a cytotoxic sputum cell or a progenitor cell thereof. It has a CD3 attribute and a CD52 attribute.
- the cytotoxic T cell or the CD3 molecule and the CD52 molecule via the CD3 molecule and the CD52 molecule giving the progenitor cells major and costimulatory stimuli can produce cytotoxic T cells or their progenitor cells, and thus activated cytotoxic T cells or their Proliferation can be induced in progenitor cells to promote proliferation, and thus cytotoxic T cells that express chemokine receptors, particularly CCR7, and can migrate to lymph nodes in a short period of time. Cytotoxic T cells having non-specific cytotoxic activity against various tumor cells, virus-infected cells and the like can be obtained.
- the cytotoxic T cells obtained by using the pharmaceutical composition of the first aspect can more accurately separate normal cells from tumor cells than other immune cells.
- the cytotoxic T cells obtained using the pharmaceutical composition of the first aspect are stimulated again with the pharmaceutical composition, so that they have a large amount of perforin and CCR7, and various tumor cells.
- cytotoxic T cells exhibiting strong and non-specific cytotoxic activity against virus-infected cells and the like can be obtained.
- the pharmaceutical composition of the first aspect capable of exhibiting such an effect is either directly (eg, administration of an agonist to a living body) or indirectly (cytotoxicity of a disease) such as a malignant tumor or a viral infection. For the production of sex T cells).
- the present inventor has conducted intensive studies on the efficacy of CD52 agonists such as anti-4C8 antibody on cytotoxic T cells or their progenitor cells.
- CD52 agonists such as anti-4C8 antibody
- cytotoxic T cells or their progenitor cells When activated by stimulating (costimulatory) cytotoxic T cells or their progenitor cells via CD3 molecules and CD52 molecules by CD3 and CD52 agonists, Based on the results, it is possible to construct a cytotoxic T cell or progenitor cell obtained by sputum for the first time when it is newly found that a chemokine receptor, particularly CCR7, is highly expressed.
- the D52 agonist has an anti-4C8 antibody or fragment thereof!
- the CD52 agonist has Campus-1H or a fragment thereof.
- the cytotoxic T cell or anti-C4C8 antibody or fragment thereof or campus 1H or fragment thereof By applying costimulation to its progenitor cells, many cytotoxic T cells can express chemokine receptors, especially CCR7, and in particular, cytotoxic T cells or their progenitor cells with anti-4C8 antibodies or fragments thereof By giving a co-stimulation to, chemokine receptors, particularly CCR7, can be expressed in more cytotoxic T cells.
- the CD52 agonist in the pharmaceutical thread and composition according to any one of the first to third aspects, is a cytotoxic T cell or a progenitor cell thereof.
- the antibody or the antibody thereof binds to one site of the CD52 molecule of the cytotoxic T cell or its precursor cell in the pharmaceutical composition of the fourth aspect.
- the fragment consists of an anti-4C8 antibody or fragment thereof, and the other antibody or fragment thereof that binds to other sites of the CD52 molecule of the cytotoxic T cell or its progenitor cell consists of campus-1H or a fragment thereof.
- an anti-4C8 antibody or a fragment thereof is bound to one site of the CD52 molecule and added.
- Campus 1H or a fragment thereof By binding Campus 1H or a fragment thereof to other sites of the CD52 molecule, cytotoxic T cells or progenitor cells thereof can be activated appropriately.
- the CD3 agonist in the pharmaceutical thread composition of any one of the first to fifth aspects, is a cytotoxic T cell or a progenitor cell thereof. Having an anti-CD3 antibody or fragment thereof that binds to the CD3 molecule.
- At least one of CD3 agonist and CD52 agonist is humanized. It has at least one of an antibody and a human antibody.
- the antibody is a mouse humanized antibody or a rat human antibody antibody campus 1H.
- the pharmaceutical composition according to the ninth aspect of the present invention comprises a CD52 agonist that provides stimulation to cytotoxic T cells or their progenitor cells.
- the CD52 agonist gives a costimulation to the cytotoxic T cell or its precursor cell via the CD52 molecule.
- a cytotoxic T cell or its progenitor cell is given a major stimulus via a CD3 molecule based on the binding of MHC-1 molecule to the T cell receptor of the cytotoxic T cell or its progenitor cell, etc. It is possible to produce a strong activity in cytotoxic T cells or their progenitor cells, and to induce strong differentiation of cytotoxic T cells or their progenitor cells thus activated.
- cytotoxic T cells that express chemokine receptors, especially CCR7, and can migrate to the lymph nodes can be easily increased in a short period of time.
- chemokine receptors especially CCR7
- cytotoxic T cells having non-specific cytotoxic activity can be obtained.
- the pharmaceutical composition of the ninth aspect capable of exhibiting such an effect is related to the effect of the present inventor on the cytotoxic T cell or its progenitor cell of CD52 agonist such as anti-4C8 antibody as described above. It can be configured for the first time based on the results obtained through intensive studies.
- the CD52 agonist has an anti-4C8 antibody or a fragment thereof!
- the CD52 agonist has Campus-1H or a fragment thereof.
- a method for cell activity that can easily obtain cytotoxic T cells having non-specific cytotoxic activity against various tumor cells, virus-infected cells and the like in a short period of time. And a method for producing cells and a pharmaceutical composition using the same. Furthermore, according to the present invention, it is possible to provide cytotoxic ⁇ cells having non-specific cytotoxic activity against various tumor cells, virus-infected cells and the like, and pharmaceutical compositions containing the same.
- the pharmaceutical composition of this example is used to bind cytotoxic T cells or progenitor cells via CD3 molecules of cytotoxic T cells or progenitor cells of cytotoxic T cells (hereinafter referred to as progenitor cells).
- CD3 molecules of cytotoxic T cells or progenitor cells of cytotoxic T cells hereinafter referred to as progenitor cells.
- the cytotoxic T cell or progenitor cell to which stimulation (costimulation) by CD3 agonist and CD52 agonist is given has at least CD8 molecule, CD3 molecule and CD52 molecule in this example.
- Cytotoxic T cells or progenitor cells consist of mononuclear cells that can be present in peripheral blood, lymph nodes, thymus, bone marrow, tumor, pleural effusion, ascites or umbilical cord blood, preferably peripheral blood that can be present in peripheral blood Also mononuclear ball power.
- the progenitor cells are embodied by, for example, CD8T cells (including CD8 + CD28 ⁇ T cells etc.) before activation.
- the CD3 agonist in this example acts on a CD3 molecule expressed on the surface of a cytotoxic T cell or progenitor cell, and transmits a signal into the cytotoxic T cell or progenitor cell via this CD3 molecule. By doing so, it also becomes a material force that causes main stimuli.
- the CD52 agonist in this example acts on the CD52 molecule expressed on the cell surface of cytotoxic T cells or progenitor cells, and transmits signals into the cytotoxic T cells or progenitor cells via this CD52 molecule. By doing so, it also becomes a material force that causes a secondary stimulus.
- the CD3 antigen contains an anti-CD3 antibody as a main active ingredient.
- the anti-CD3 antibody is recognized by the cytotoxic T cell or progenitor cell by binding to the CD3 molecule of the cytotoxic T cell or progenitor cell.
- the CD3 antigen contains an anti-CD3 antibody fragment that binds to and is recognized as an active ingredient in the same manner as the anti-CD3 antibody, instead of or in addition to the anti-CD3 antibody. It is preferable that such a fragment consists of a Fab fragment having an antigen recognition site.
- the anti-CD3 antibody may be configured as a humanized antibody (including mouse humanized antibody, rat humanized antibody, etc.) or a human antibody.
- Anti-CD3 antibodies that are agonistic to the CD3 molecule include, for example, OKT3 (ATCC CRL—8001), UCHT1 (BD Pharmingen), and HIT3a (BD Pharmingen).
- the CD3 antigen may contain any molecule that can be a natural or synthetic ligand for the CD3 molecule in addition to the anti-CD3 antibody described above.
- the T3 antigen receptor and the CD3 may contain various substances that can lead to the formation of a complex consisting of molecules and signal transduction to cytotoxic T cells or progenitor cells via CD3 molecules, in particular, antibodies having an agonist action or fragments thereof.
- Such an antibody or a fragment thereof is, for example, OT145 (Posnett et al., 1986, Proc. Natl. Acad. Sci. USA., 83: 7888-92, which is an antibody against the human T cell antigen receptor Vbeta6.7. ) May be specified.
- the CD3 antigen can be used in combination with the above-mentioned anti-CD3 antibody and a T cell antigen receptor such as an HLA molecule as a soluble MHC-1 molecule, a tetramer molecule having an HLA molecule and an antigen peptide. It may contain substances that can recognize and produce an agonist action!
- the CD52 antigen contains an anti-4C8 antibody as one of the anti-CD52 antibodies as a main active ingredient.
- the anti-4C8 antibody is recognized by the cytotoxic T cell or progenitor cell by binding to the CD52 molecule of the cytotoxic T cell or precursor cell.
- the CD52 antigen may contain a fragment of the recognized anti-4C8 antibody that binds to and recognizes the CD52 molecule in the same manner as the anti-4C8 antibody instead of or in addition to the anti-4C8 antibody.
- a fragment preferably comprises a Fab fragment having an antigen recognition site.
- cytotoxic T cells or progenitor cells that are co-stimulated by anti-4C8 antibody or a fragment thereof have strong production of cytoforce-ins such as interferon ⁇ (IFN- ⁇ ) and IL-2, which have antitumor effects. Can be induced.
- IFN- ⁇ interferon ⁇
- IL-2 interferon ⁇
- the class of anti-4C8 antibodies is IgG3.
- the anti-4C8 antibody may be configured as a humanized antibody (including a mouse human antibody, a rat humanized antibody, etc.) or a human antibody.
- a humanized antibody can be obtained, for example, by transplanting the variable region of an anti-CD52 antibody produced by Hypridoma JM-1 into a human antibody framework.
- the human antibody is, for example, rearranged !, a mouse that retains the human antibody gene and produces a human antibody specific to the antigen by auditing the antigen (for example, Tomizuka et al., 2000). , Proc. Natl. Acad. Sci. USA., 97: 722).
- the CD52 antigen is a natural or synthetic ligand that binds to the CD52 molecule instead of or in addition to the anti-4C8 antibody, in other words, any molecule or antigen that induces a signal through the CD52 molecule.
- a molecule or antibody which may contain an antibody against the CD52 molecule, may recognize any part of the CD52 molecule. Any device can be used as long as it can transmit a signal.
- the CD52 antigen is, for example, a campus 1H that may contain as an active ingredient Campus 1H (Campath-1H) or a fragment thereof that binds to the CD52 molecule instead of or in addition to the anti-4C8 antibody.
- the fragment preferably consists of a Fab fragment having an antigen recognition site.
- Campus 1H means, in this example, rat humanized antibody campus 1H (rat human antibody Campath-1H) that binds to the CD52 molecule.
- Campus-1H is known, for example, as a therapeutic agent for B cell lymphoma patients and as an antibody that removes peripheral blood lymphocytes. In this example, however, costimulation is performed on cytotoxic T cells or progenitor cells. Used as one of the antibodies to give.
- CD52 antigens contact cells expressing a CD52 molecule with a candidate compound, and detect the interaction or CD52 stimulation response. Screening using the interaction with CD52 as an index. Obtained by doing.
- the CD52 antigen may contain any molecule that can be a natural or synthetic ligand for the CD52 molecule in addition to the anti-4C8 antibody described above.
- Anti-4C8 antibodies and molecules that can be ligands are reported by Masuyama et al. (Masuyama, J. et al., 1999, J. Exp. Med. 189: 979-989; W099 / 12972) It can be obtained by selecting, from the monoclonal antibody obtained from an animal immunized with human T-filament cysts, using as an index the inhibition of in vitro extravasation of T cells.
- An anti-CD52 antibody capable of binding to an anti-4C8 antibody or a CD52 molecule other than the anti-4C8 antibody is obtained by adding human T cells to human umbilical vein endothelial cells (HUVEC) cultured in a monolayer on a collagen gel. It can be obtained by using T cells migrated under HUVEC as an antigen after a certain period of time.
- Preferred antibodies and the like contained in the CD52 antigen include an antibody selection step that recognizes the same epitope as the anti-4C8 antibody, and a step of evaluating the differentiation-inducing ability of cytotoxic T cells. It can be easily obtained by combining the above.
- the CD3 agonist gives the main stimuli to the progenitor cells via the CD3 molecule of the progenitor cells, and the CD3 agonist Along with this main stimulation, the CD52 antigen gives a costimulation to the progenitor cell via the CD52 molecule of the progenitor cell.
- the primary stimulation of cytotoxic T cells or progenitor cells by CD3 agonists occurs through the main stimulus transmission pathways involved in the differentiation of cytotoxic T cells or progenitor cells. Primary stimulation by CD3 agonists triggers a response when promoting differentiation of cytotoxic T cells or progenitor cells.
- Costimulation of cytotoxic T cells or progenitor cells by CD52 agonists occurs through other stimulus transmission pathways.
- the CD52 antigen co-stimulates cytotoxic T cells or progenitor cells at the same time as or before or after the main stimulation by the CD3 antigen.
- Progenitor cells given major and minor stimuli by CD3 and CD52 agonists are induced based on these stimuli to differentiate and proliferate into cytotoxic T cells with cytotoxic activity. .
- Such cytotoxic T cells as shown in the Examples below, are highly expressed by chemokine receptors, particularly CCR7, and thus migrate to organs and lymph nodes subordinate to the organs. It has such a high degree of mobility as to be able to be performed, and also has a high killing ability against tumor cells, virus-infected cells and the like.
- the cytotoxic T cell having na ⁇ ve T cell or memory T cell power is activated using the pharmaceutical composition of this example
- the cytotoxic T cell is activated in the same manner as in the case of activating the progenitor cell. Giving cells primary and secondary stimuli. Cytotoxic T cells given primary and secondary stimuli are induced to differentiate and proliferate based on these stimuli.
- cells that have been activated and proliferated using the pharmaceutical composition of this example proliferate upon stimulation by a CD52 agonist and a CD52 agonist having an anti-4C8 antibody or an anti-4C8 antibody fragment.
- a cytotoxic T cell a cytotoxic T cell having a large amount of perforin and CCR7 can be obtained. With high amounts of perforin and CCR7, cytotoxic T cells are highly chemotactic for CCR7 ligand and tumor cells, viruses It can show a higher killing ability against infected cells and the like.
- the pharmaceutical composition of this example may be used by being contained in a drug such as a buffer solution, capsule, granule, powder, syrup or the like that is orally administered into a living body.
- a pharmaceutical composition administered in vivo which may be used by being contained in a medicine comprising an injection, infusion, suppository, etc. administered parenterally into a living body by intramuscular injection, intravenous injection, etc. It may be used in a drug together with various additives such as carriers, pH buffers, stabilizers, and excipients that may be lyophilized and acceptable for therapeutic effects.
- the drug containing the pharmaceutical composition preferably further contains a physiologically acceptable diluent or carrier.
- Such carriers may be, for example, physiological saline, phosphate buffered physiological It may be specified by using saline, phosphate buffered saline glucose solution, buffered saline, or a combination thereof.
- the pharmaceutical composition also includes immune cells such as cytotoxic T cells and progenitor cells collected from patients or humans other than patients, particularly T cells and peripheral blood, lymphocytes, lymph node cells, and thymus containing these cells.
- cytotoxic T cells activated in vitro, differentiated, proliferated, or enhanced in function may be used for cells, umbilical cord blood, tumor tissue, etc. Or it is transferred into the living body of another family.
- the administration method and dosage of the pharmaceutical composition are appropriately determined in relation to the preclinical test and the clinical trial process.
- the dose is usually about 0. Olmg to lOOOmg per day for an adult, and such oral administration is performed once or divided into several times.
- the dose is usually about 0. Olmg to lOOOmg per adult.
- the dose of the pharmaceutical composition by oral administration or parenteral administration is determined according to age, body weight, and disease symptoms.
- the medicinal thread and adult product can be reproduced as the experimental system developed in the field of basic research almost as it is in the field of therapy! Ex vivo) may be used. Since the etas vivo method activates cytotoxic T cells or progenitor cells in vitro, administration of the pharmaceutical composition in vivo is absorbed in the body, metabolized, or interfered by unknown factors. In view of the fact that the expected therapeutic effect may not be achieved due to factors such as the above, it is considered a relatively low-risk method for practical application.
- the hybridoma that produces the monoclonal antibody is according to Hypridoma JM-1 (deposited with the Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology as of September 26, 2001 under the accession number FERMBP-7757).
- Hypridoma JM-1 deposited with the Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology as of September 26, 2001 under the accession number FERMBP-7757.
- the anti-4C8 antibody produced as a competitive reagent T cell staining by the test antibody is suppressed, in other words, recognizing the same epitope as the anti-CD52 antibody produced by Hypridoma JM-1. Can be easily obtained by combining these as indicators.
- the cytotoxic T cells activated by the pharmaceutical composition of this example proliferate more easily in the presence of IL2. Cytotoxic T cells proliferated in the presence of IL-2 induce more perforin when re-stimulated with anti-4C8 antibody, resulting in higher killing ability against tumor cells, virus-infected cells, etc. .
- the second costimulation with the anti-4C8 antibody or a fragment thereof against the cytotoxic T cell is given together with the main stimulation with the CD3 antigen.
- the CD3 molecule and the CD52 molecule are used as the CD3 molecule and the CD52 molecule.
- main and accessory stimuli to cytotoxic T cells or their progenitor cells via the cell, it is possible to generate a strong activity in the cytotoxic T cells or their progenitor cells.
- cytotoxic T cells obtained by using the pharmaceutical composition of this example can more accurately separate normal cells from tumor cells than other immune cells.
- the tumor composition has a large amount of perforin and CCR7, and various tumor cells, It is possible to obtain cytotoxic T cells that exhibit strong and non-specific cytotoxic activity against virus-infected cells and the like.
- the CD52 antigen has an anti-4C8 antibody or fragment thereof, or campus 1H or a fragment thereof
- the anti-4C8 antibody or fragment or
- many cytotoxic sputum cells can express chemokine receptors, especially CCR7, especially anti-4C8 antibodies
- a chemokine receptor, particularly CCR7 can be expressed in a larger number of cytotoxic sputum cells by co-stimulating the cytotoxic sputum cells or progenitor cells thereof with a fragment thereof.
- the CD52 antigen has an anti-4C8 antibody or a fragment thereof and cannos 1H or a fragment thereof
- the anti-4C8 antibody or a fragment thereof is linked to one site of the CD52 molecule.
- the cytotoxic or progenitor cell can be activated appropriately.
- the pharmaceutical composition of this example can be used directly (for example, administration of an agonist to a living body) or indirectly (for example, production of cytotoxic vaginal cells) for the treatment of diseases and pathological conditions such as malignant tumors and viral infections. .
- the pharmaceutical composition of the present example capable of exhibiting such effects was studied by the present inventor with regard to the efficacy of CD52 agonists such as anti-4C8 antibody on cytotoxic T cells or their progenitor cells. Cytotoxicity obtained by stimulating (co-stimulating) cytotoxic T cells or their progenitor cells via CD3 molecules and CD52 molecules by activation and CD52 agonist If it is newly found that sex T cells or their progenitor cells express high levels of chemokine receptors, particularly CCR7, they can be constructed based on the results.
- the other pharmaceutical composition of this example contains a CD52 agonist having an anti-4C8 antibody or a fragment thereof as a main active ingredient.
- a pharmaceutical composition for example, by giving a costimulation to a cytotoxic T cell or a progenitor cell thereof via a CD52 molecule by a CD52 agonist, When a major stimulus via CD3 molecule is applied based on the binding of MHC-1 molecule to the T cell receptor of T cell or its progenitor cell, it has a strong activity on cytotoxic T cell or its progenitor cell.
- Cytotoxic T cells having non-specific cytotoxic activity against cells and the like can be obtained.
- Example 1 a test is performed on the expression of CCR7 and perforin in cytotoxic sputum cells induced by costimulation with CD52 agonist.
- peripheral blood mononuclear cells of healthy individuals were separated by density gradient centrifugation using Ficoll-Paque Plus (Amersham Pharmacia), and the separated mononuclear cells were passed through a nylon wool column, and the flow-through fraction was separated. Harvested to obtain T cells.
- CD8 T cells having CD8 molecules were isolated from T cells by negative selection using MACS CD8 + T cell Isolation Kit (Milteny Biotec).
- MACS CD8 + T cell Isolation Kit MACS CD8 + T cell Isolation Kit (Milteny Biotec).
- MACS CD8 + T cell Isolation Kit MACS CD8 + T cell Isolation Kit (Milteny Biotec).
- phosphate buffer (PBS) phosphate buffer
- the isolated CD8T cells were suspended in RPMI1640 medium (10% FCS + 15 mM HEPES + 1% penicillin + 1% streptomycin) at a concentration of 1 X 10 6 Zml, and anti-CD3 antibody and anti-4C8 antibody or campus 1 ⁇ 10 6 pieces of 0.5 force were also added to each hole of the 48-well plate treated with 1H. After culturing for 4 days at 37 ° C using a CO incubator,
- the solution was adjusted to X 10 6 Zml and transferred to another culture vessel, and IL 2 (20 UZml) was added to continue the culture.
- the culture medium was changed by half every other day, and IL 2 (20 UZml) was added every time the medium was changed.
- T cells were collected and washed. Over 99% of the collected T cells were CD8 positive and TCR a ⁇ positive.
- the second costimulation was given to CD8T cells via the CD52 molecule.
- Anti-CD3 antibody and anti-4C8 antibody were immobilized. 1 ⁇ 10 7 collected T cells were added to the well plate and cultured in a CO incubator. culture
- CD8T cells were recovered after 4 days from the start, and the CD8T cells were used for the experiment.
- CD3-LAK cells to be compared were obtained by the following general method.
- an anti-CD3 antibody 5 gZml
- 1 ⁇ 10 6 T cells which are nylon wool column passage fractions of peripheral blood mononuclear cells, were seeded.
- IL-2 100 UZml was added 24 hours and 72 hours after seeding, and cultured for a total of 5 days.
- the plates were then transferred and the cells were grown for about 10 days with IL 2 (20 U / ml) added every other day for growth.
- CD52—CTL 3 x 10 5 CD8T cells (hereinafter referred to as CD52—CTL) treated with costimulation of CD52 molecules were suspended in 50 ⁇ l of the culture solution, and then FITC-labeled anti-CCR7 antibody (Dako) ) Was placed on ice and in the dark for 30 minutes. After standing, the cells were washed twice with PBS supplemented with 0.1% ushi serum albumin, fixed with l% paraformaldehyde, and the expression of CCR7 (positive) on the living cell surface was examined by FACScan.
- CTL CD8T cells
- CD3- LAK cells CCR 7+ expression (%), since the front is below CCR 7+ expression CD8T cells (%), CD3-LAK cells force be suggested to CCR7 + is disappeared Yes.
- C As shown in Fig. 2, the average fluorescence intensity of D52—CTL perforin in cells is significantly higher in CD52—CTL after the second stimulation than in CD52—CTL before the second stimulation. It has also been suggested that CD52-CTL intracellular perforin increases markedly after the second stimulation.
- Example 2 a test on chemotaxis (chemotaxis) reaction to CCR7 ligand was performed, and CD52—CTL with high expression of CCR7 reacted to CCR7 ligand, and chemotaxis was enhanced! / Consider whether or not.
- Chemotaxis assembly was performed using Transwell S ⁇ um pore, polycarbonate, Costar) for 24-well plates.
- the CCR7 ligand chemokine CCL21 (R & D) was added to the lower chamber of Transwell at concentrations of 10 ngZml, lOOngZml and lOOOngZml, respectively.
- CCL20 (R & D) which is a ligand of CCR6 that is not expressed in CD52-CTL and CD3-LAK, was used.
- 5 ⁇ 10 5 CD52-CTL or CD3 LAK were added and cultured at 37 ° C. After 90 minutes from the start of the culture, the cells that migrated to the lower chamber were counted.
- the chemotaxis activity (%) was determined using the following formula (1).
- Chemotaxis activity Number of cells moving in the lower chamber Z Number of cells added in the upper chamber ⁇ ⁇ ⁇ ⁇ (1)
- CD52-CTLs are found to move actively due to the chemotaxis reaction of CCR7 and CCL21.
- CD52-CTLs are administered in vivo, the majority of the CD52-CTLs are Suggested that can reach the lymph nodes It is.
- Example 3 a test for the cytotoxic activity of CD52-CTL against cancer cells and normal cells is performed.
- cytotoxic activity For analysis of cytotoxic activity, a standard 4 hour 51 Cr release assay was used. The target cells were labeled with 51 Cr 100 Ci and washed, and 1 x 10 4 washed target cells were placed in each well of a 96-well round bottom plate (ICN), with an E / T ratio (effector of 6 to 50). CD52-CTL was added at a cell / target cell ratio. Incubate at 37 ° C for 4 hours in a CO incubator.
- the 51 Cr radioactivity released into the supernatant 100 1 was measured with a gamma counter.
- the cytotoxic activity (%) was determined using the following formula (2).
- KatoIII gastric cancer
- TE11 esophageal cancer
- Daudi Backitt lymphoma
- CD52—CTL is cytotoxic against KatoIII and TE11 depending on the CD52—CTLZ target cell ratio (EZT ratio). (%).
- CD52-CTL suggested cytotoxic activity (%) against Daudi independent of the CD52-CTLZ target cell ratio.
- CD52-CTL showed no cytotoxic activity (%) against ConA-Blasts (Con-A) as normal cells.
- Example 4 a test is conducted on the cytotoxic activity of CD52-CTL cultured for 24 hours against tumor cells.
- Tumor cell lines include KatoIII (gastric cancer), TE11 (esophageal cancer), TE2 (esophageal cancer), WiDr—TC (colorectal cancer), SK-MEL-28 (malignant melanoma), LCSC # 1 (lung) Adenocarcinoma), LU65 (small cell lung cancer) ) was used.
- Target tumor cells 1 X lOVml (SK MEL-28 only 0.5 X lO ml) is seeded 100 1 in each well of a 96-well flat-bottom plate, and tumors are cultured in a 5% CO incubator at 37 ° C for 3 hours.
- the cells were cultured until the tumor cells fully adhered to the 96-well flat bottom plate. This CD52-CTL was added at a predetermined EZT ratio of 100 1 and cultured at 37 ° C for 24 hours in a 5% CO incubator. Culture
- cytotoxic activity (%) was measured by adding 10% of WST-1 (Roche's Diagnostic Status) and culturing for 2 hours, using an ELISA plate reader at 2 wavelengths of A49 2nmZA620nm. Obtained using (3).
- TS means target cells only
- BGO means background of culture medium only
- E means target cells and CD52-CTL (effector cells)
- BGEC means background of effector cells only means.
- the cytotoxic activity (%) depending on the EZT ratio of CD52-CTL induced by costimulation via CD52 molecule with anti-4C8 antibody is It is potent against each of the six types of tumor cells and shows a non-specific tendency towards these tumor cells.
- Example 5 a test for the enhancing action of IL2 on CD52-CTL is performed.
- Example 6 the cytotoxic activity (%) of CD52—CTL given costimulation by anti-4C8 antibody and the cytotoxic activity of CD52—CTL given costimulation by campus 1H (%) %) Is compared.
- CD52-CTL which is co-stimulated by Karasu Campus 1H, can have a sufficient antitumor effect even when used for the treatment of tumor cells.
- Example 7 CD3— LAK cells and CD52— CTL cells for monolayer culture LCSC # 1 (obtained from Medical Cell Resource Center, Tohoku University Institute of Medical Research, including lung adenocarcinoma and other cancer cells) And a test for comparison of cytotoxic activity.
- LCSC # 1 was cultured in RPMI 1640 supplemented with 10% FCS in a 24-well plate (coning) until it became a monolayer.
- T cells were obtained by separating peripheral blood mononuclear cells (PBM C) from healthy individuals and further passing through a nylon wool column.
- the T cell antibody stimulation obtained in this way has a range of solid-phase antibody concentrations effective for T cell stimulation (anti-CD3 antibody lOOngZml 5 ⁇ g / ml, anti-4C8 antibody and campus— 1H 1-50 ⁇ gZ ml), an antibody amount different from that in Example 1 was used.
- CD3-LAK cells were induced by stimulation for 3 days using a 48-well plate with anti-CD3 antibody (lOOngZml) immobilized on it, and the addition of IL 2 (lOOUZml) was repeated every 3 days. The culture was grown for 2 weeks while replacing with a new plate.
- the first CD52 costimulation of CD52—CTL cells was performed on T cells using a plate with anti-CD3 antibody (lOOngZml) and anti-4C8 antibody (5 ⁇ g / ml) immobilized. For 3 days, and then IL-2 (100 UZml) was collected every 3 days and grown for 2 weeks in place of a large plate. Double-stimulated CD52—CTL cells are as described 1 This was obtained by culturing a part of the T cells given the second CD52 costimulation with a second CD52 costimulation for 3 days. In this culture method, ⁇ cells proliferated 100 to 1000 times. In addition, in this culture method, CD8 + T cells accounted for about 80%.
- LCSC # 1 was cultured and monolayered in the same manner as in Example 7, and then treated with trypsin for a short time. After separation by trypsin treatment, washed and suspended in PBS was used. T cell culture medium is AIM-V (Invitrogen) with 5% autologous plasma in consideration of actual clinical use. The thing which added was used.
- AIM-V Invitrogen
- T cells were obtained from healthy individuals in the same manner as in Example 7.
- CD3-LAK cells were induced by stimulating for 3 days using a 48-well plate with anti-CD3 antibody (lOOngZml) immobilized, and then supplemented with IL-2 (100 UZml) every 3 days. The ones grown in culture for 2 weeks while using large plates were used.
- CD52—CTL cells can be obtained from the first round of T cells using a plate with anti-CD3 antibody (100 ⁇ g / ml) and 1H (20 ⁇ g / ml) immobilized on campus instead of anti-4C8 antibody.
- SCID mice 7 weeks old, female, obtained from CLEA Japan
- anti-asharo GM1 antibody (Wako Pure Chemical) 100 gZ mice
- Three SCID mice were divided into 3 groups (Group A, Group B and Group C).
- Group A consisted of 3 SCID mice that were intraperitoneally transferred with LCSC # 1 (1 X 10 7 mice / mouse) only.
- Group B LCSC # 1 (1 X 10 7 Z mice) was transferred intraperitoneally, and CD3 LAK cells (4 X 10 7 Z mice) were injected intraperitoneally on the 3rd and 5th day after the transfer.
- group C LCSC # 1 (1 X 10 7 Z mice) was transferred intraperitoneally, and CD52-CTL (4 X 10 7 Z mice) was injected intraperitoneally on the 3rd and 5th day after the transfer.
- FIG. 1 is an explanatory diagram relating to test results in Example 1.
- FIG. 1 is an explanatory diagram relating to test results in Example 1.
- FIG. 2 is an explanatory diagram relating to test results in Example 1.
- FIG. 3 (a) and (b) are explanatory diagrams relating to test results in Example 2.
- FIG. 3 (a) and (b) are explanatory diagrams relating to test results in Example 2.
- FIG. 4 is an explanatory diagram regarding test results in Example 3.
- FIG. 5 is an explanatory diagram regarding test results in Example 4.
- FIG. 6 is an explanatory diagram relating to test results in Example 5.
- FIG. 7 is an explanatory diagram relating to test results in Example 6.
- FIG. 8 is an explanatory diagram relating to test results in Example 7.
- FIG. 9 is an explanatory diagram relating to test results in Example 8.
Abstract
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-343759 | 2003-10-01 | ||
JP2003343759 | 2003-10-01 | ||
JP2004218569A JP2005124568A (ja) | 2003-10-01 | 2004-07-27 | 細胞活性化方法及びこれを用いる細胞製造方法並びに医薬組成物 |
JP2004-218569 | 2004-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005033301A1 true WO2005033301A1 (ja) | 2005-04-14 |
Family
ID=34425338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/014170 WO2005033301A1 (ja) | 2003-10-01 | 2004-09-28 | 細胞活性化方法及びこれを用いる細胞製造方法並びに医薬組成物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2005124568A (ja) |
WO (1) | WO2005033301A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006340698A (ja) * | 2005-06-10 | 2006-12-21 | Cellex:Kk | Nk細胞活性化方法、これを用いたnk細胞増殖方法及び細胞製造方法並びにnk細胞を含む単核球 |
JP2010239972A (ja) * | 2010-07-22 | 2010-10-28 | Cellex:Kk | Nk細胞活性化方法、これを用いたnk細胞増殖方法及び細胞製造方法並びにnk細胞を含む単核球 |
JP2013143970A (ja) * | 2013-05-01 | 2013-07-25 | Cellex:Kk | Nk細胞活性化方法、これを用いたnk細胞増殖方法及び細胞製造方法並びにnk細胞を含む単核球 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011001315A (ja) * | 2009-06-19 | 2011-01-06 | Cellex Corp | 膵臓癌の免疫療法剤 |
SG11202100829SA (en) * | 2018-08-10 | 2021-03-30 | Univ Kyoto | Method for producing cd3-positive cell |
-
2004
- 2004-07-27 JP JP2004218569A patent/JP2005124568A/ja active Pending
- 2004-09-28 WO PCT/JP2004/014170 patent/WO2005033301A1/ja active Application Filing
Non-Patent Citations (2)
Title |
---|
ROWAN W. ET AL.: "Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells", IMMUNOLOGY, vol. 95, no. 3, 1998, pages 427 - 436, XP000942636 * |
WALDMANN T.A. ET AL.: "Emerging therapies: spectrum of applications of monoclonal antibody therapy", HEMATOLOGY (AM- SOC. HEMATOL. EDUC. PROGRAM), 2000, pages 394 - 408, XP002984219 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006340698A (ja) * | 2005-06-10 | 2006-12-21 | Cellex:Kk | Nk細胞活性化方法、これを用いたnk細胞増殖方法及び細胞製造方法並びにnk細胞を含む単核球 |
JP4645312B2 (ja) * | 2005-06-10 | 2011-03-09 | 株式会社セレックス | Nk細胞活性化方法、これを用いたnk細胞増殖方法及び細胞製造方法並びにnk細胞を含む単核球 |
JP2010239972A (ja) * | 2010-07-22 | 2010-10-28 | Cellex:Kk | Nk細胞活性化方法、これを用いたnk細胞増殖方法及び細胞製造方法並びにnk細胞を含む単核球 |
JP2013143970A (ja) * | 2013-05-01 | 2013-07-25 | Cellex:Kk | Nk細胞活性化方法、これを用いたnk細胞増殖方法及び細胞製造方法並びにnk細胞を含む単核球 |
Also Published As
Publication number | Publication date |
---|---|
JP2005124568A (ja) | 2005-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016238963B2 (en) | Method and compositions for cellular immunotherapy | |
Chu et al. | Natural killer cells: a promising immunotherapy for cancer | |
US9789174B2 (en) | Method for proliferation of antigen-specific T cells | |
AU2001236621B2 (en) | Cd40-binding apc-activating molecules | |
JP6389166B2 (ja) | 抗b7−h6抗体、融合タンパク質、及びこれらを使用する方法 | |
KR20170031139A (ko) | 시토킨 조성물을 이용한 능동 세포적 면역 치료법을 위한 림프구의 증식 | |
US9657269B2 (en) | Regulatory B cells (tBREGS) and their use | |
Mikelez-Alonso et al. | Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: A look into how nanoparticles enhance NK cell activity | |
WO2010141093A2 (en) | Co-signaling methods for treating cancers | |
CN113402619B (zh) | 一种靶向B7H3共表达IL-21的全人源嵌合抗原受体、iNKT细胞及其用途 | |
JP2020527036A (ja) | 癌免疫療法用mr1制限t細胞受容体 | |
WO2013167136A1 (en) | Improving adoptive cell therapy with interferon gamma | |
JP3904374B2 (ja) | キラー活性を増強したリンパ球 | |
Morecki et al. | Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody | |
CN112426526A (zh) | 一种nk细胞的制备方法及其在治疗癌症中的应用 | |
Yoon et al. | Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR) | |
WO2005033301A1 (ja) | 細胞活性化方法及びこれを用いる細胞製造方法並びに医薬組成物 | |
Li et al. | Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer | |
EP3191109B1 (en) | A cell population for use in treating cancer | |
US20220106402A1 (en) | Antibody | |
EP4052716A1 (en) | Cancer therapy involving car-engineered t-cells and parvovirus h-1 | |
Mobasheri et al. | The Role of Gamma Delta T Cells in Cancer | |
Liu et al. | Tumor-associated protein ligands recognized by human T cell receptor and their implications in cancer therapy | |
Osada et al. | Natural killer cell activation and dendritic cell-based vaccines | |
NZ726162B2 (en) | Method and compositions for cellular immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |